Amedisys
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 19K
- Market Cap
- -
- Introduction
Amedisys, Inc. engages in the provision of healthcare services. It operates through the following business segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment delivers services in the homes of individuals who may be recovering from an illness, injury, or surgery. The Hospice segment provides care that is designed to provide comfort and support for those who are facing a terminal illness. The Personal Care segment gives patients assistance with the essential activities of daily living. The High Acuity Care segment includes providing home care recovery for high acuity patients on either a full risk or limited risk basis. The company was founded in 1982 and is headquartered in Baton Rouge, LA.
GeneFab and RegCell Partner to Advance Novel Treg Cell Therapy for Autoimmune Diseases into US Clinical Trials
• RegCell has partnered with GeneFab to transfer and manufacture its regulatory T cell (Treg) therapy platform for autoimmune diseases, with initial focus on autoimmune hepatitis.
• The collaboration leverages GeneFab's 92,000 square foot Alameda facility with seven GMP clean rooms to provide end-to-end CRDMO support for RegCell's epigenetic reprogramming platform.
• RegCell recently secured $45.8 million in funding, including $8.5M from seed financing and up to $37.3M from Japan's AMED, as it transitions its headquarters to the US and aims for first-in-human trials in 2025.
CAR-Enhancers Show Promise in Prolonging Remission in CAR T-Cell Therapy
• Researchers at Dana-Farber Cancer Institute have developed CAR-enhancers (CAR-E) to extend the effectiveness of CAR T-cell therapy.
• CAR-E aims to prevent relapse by maintaining the activity of CAR T-cells and promoting the formation of memory cells.
• The new CAR-E therapy is set to begin a phase I clinical trial focusing on safety, dosage, and treatment schedule post CAR T-cell infusion.
• CAR T-cell therapy, while effective for blood cancers, faces challenges with relapse due to T-cell exhaustion.
© Copyright 2025. All Rights Reserved by MedPath